Alexander Chaitoff, MD, MPH
Assistant Professor of Internal Medicine
Department of Internal Medicine, Division of General Medicine
2800 Plymouth Rd. B16-332W
Ann Arbor, MI 48109
[email protected]

Available to mentor

Alexander Chaitoff, MD, MPH
Assistant Professor
  • About
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications
  • About

    Dr. Chaitoff is a Research Scientist in the Center for Clinical Management Research at the Veterans Affairs Ann Arbor Health System and an Assistant Professor in the Department of Internal Medicine at the University of Michigan Medical School. He attended medical school at the Cleveland Clinic Lerner College of Medicine and completed both Internal Medicine residency and a research fellowship in implementation science at Brigham and Women’s Hospital/Harvard Medical School. A clinician-researcher, he is interested in re-evaluating the safety and efficacy of medications as adults age and then finding the best ways to get older adults onto the most appropriate treatment regimens. His work has appeared in numerous high-impact journals including JAMA JAMA Internal Medicine, Diabetes Care, and Annals of Internal Medicine.

    Qualifications
    • Research Fellow
      Brigham and Women's Hospital/ Harvard Medical School, Boston, 2024
    • Residency
      Brigham and Women's Hospital, Department of Internal Medicine, 2022
    • Internship
      Brigham and Women's Hospital, Department of Internal Medicine, 2020
    • MD
      Cleveland Clinic Lerner College of Medicine, Cleveland, 2019
    • MPH (with merit)
      University of Sheffield, Sheffield, 2015
    • BS
      Ohio State University, Columbus, OH, 2013
    Center Memberships
    • Center Member
      Institute for Healthcare Policy and Innovation
    Research Overview

    His research interests include identifying low-value care and finding the most efficacious methods to deprescribe it.

    • Medication optimization in older adults
    • Medication safety
    • Disparities in medication use
    • Implementation science

    Recent Publications See All Publications
    • Journal Article
      Estimating New Eligibility and Maximum Costs of Expanded Medicare Coverage of Semaglutide for Cardiovascular Risk Prevention.
      Chaitoff A, Bendicksen L, Feldman WB, Zheutlin AR, Lalani HS. Ann Intern Med, 2024 Oct; 177 (10): 1440 - 1442. DOI:10.7326/ANNALS-24-00308
      PMID: 39186788
    • Presentation
      Less is more…sometimes? Maybe? The state of evidence for deprescribing and directions for the future, medical grand rounds
      Chaitoff A. 2024 Jun;
    • Additional Scholarship
      The Main Course – An Update to Breast Cancer Screening Recommendations (Curbsiders Digest)
      Chaitoff A. 2024 Jun;
    • Additional Scholarship
      The Main Course – Cancer Drug Approval – Is There Such a Thing as Too Fast (Curbsiders Digest)
      Chaitoff A. 2024 Apr;
    • Journal Article
      Testing interventions to reduce clinical inertia in the treatment of hypertension: rationale and design of a pragmatic randomized controlled trial.
      Haff N, Sreedhara SK, Wood W, Yom-Tov E, Horn DM, Hoover M, Low G, Lauffenburger JC, Chaitoff A, Russo M, Hanken K, Crum KL, Fontanet CP, Choudhry NK. Am Heart J, 2024 Feb; 268: 18 - 28. DOI:10.1016/j.ahj.2023.11.005
      PMID: 37967641
    • Journal Article
      Epidemiology of Hypertension in Older Adults.
      Chaitoff A, Zheutlin AR. Clin Geriatr Med, 2024 Nov; 40 (4): 515 - 528. DOI:10.1016/j.cger.2024.04.007
      PMID: 39349028
    • Journal Article
      Gabapentinoid Use by Self-Reported Indication and Level of Evidence.
      Chaitoff A, Choudhry NK, Haff N, Lauffenburger JC. J Gen Intern Med, 2024 Jan; 39 (1): 156 - 158. DOI:10.1007/s11606-023-08418-7
      PMID: 37794261
    • Additional Scholarship
      The Main Course – The Business of Healthcare is Changing (Curbsiders Digest)
      Chaitoff A. 2024 Jan;
    Featured News & Stories yellow measurement yellow twirled around blue colored money signs and RX bottles and pills and shots
    Health Lab
    The heart of the question: Who can get Medicare-covered weight loss medicine?
    Wegovy (semaglutide) now has Medicare approval for coverage among people with obesity and cardiovascular disease but no diabetes; a study looks at what level of risk might make someone eligible.